Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TLR9 | Q9NR96 | 6/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17395638 | 0.83 | QDPR (0.57) | QDPRTLR9TLR8TLR7TDP1 | |
| SCHEMBL5882387 | 0.81 | QDPR (0.47) | QDPR | |
| SCHEMBL19097560 | 0.81 | QDPR (0.54) | QDPRALDH1A1TLR9TLR8TLR7 | |
| SCHEMBL19097388 | 0.80 | QDPR (0.76) | QDPRALDH1A1MEN1KMT2A | |
| SCHEMBL19107647 | 0.77 | QDPR (0.50) | QDPRALDH1A1TDP1NAMPTHTR2B | |
| SCHEMBL17397799 | 0.76 | TLR9 (0.44) | QDPRTLR9TLR8TLR7NAMPT | |
| SCHEMBL11161163 | 0.76 | ACMSD (0.57) | QDPR | |
| SCHEMBL17397714 | 0.76 | TDP1 (0.47) | TDP1MEN1KMT2AMAPT | |
| SCHEMBL2721166 | 0.75 | ESR2 (0.53) | — | |
| SCHEMBL20884951 | 0.75 | F2R (0.58) | ALDH1A1MEN1TSHRKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3164396-B1 | CYCLOHEXEN-1-YL-PYRIDIN-2-YL-1H-PYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS AG (CH) | 2019-01-16 | — | — | EP | disclosed |
| US-9957254-B2 | Cyclohexen-1-yl-pyridin-2-yl-1h-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators | NOVARTIS AG (CH) | 2018-05-01 | — | — | US | disclosed |
| US-9765067-B2 | Thiophen-2-yl-pyridin-2-yl-1H-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators | NOVARTIS AG (CH) | 2017-09-19 | — | — | US | disclosed |
| US-9765067-B2 | Thiophen-2-yl-pyridin-2-yl-1H-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators | NOVARTIS AG (CH) | 2017-09-19 | — | — | US | disclosed |
| US-20170197950-A1 | THIOPHEN-2-YL-PYRIDIN-2-YL-1H-PYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS AG (CH) | 2017-07-13 | — | — | US | disclosed |
| US-20170197941-A1 | CYCLOHEXEN-1-YL-PYRIDIN-2-YL-1H-PYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS AG (CH) | 2017-07-13 | — | — | US | disclosed |
| US-20170197941-A1 | CYCLOHEXEN-1-YL-PYRIDIN-2-YL-1H-PYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS AG (CH) | 2017-07-13 | — | — | US | disclosed |
| US-20170197950-A1 | THIOPHEN-2-YL-PYRIDIN-2-YL-1H-PYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS AG (CH) | 2017-07-13 | — | — | US | disclosed |
| US-20170197950-A1 | THIOPHEN-2-YL-PYRIDIN-2-YL-1H-PYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS AG (CH) | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197941-A1 | CYCLOHEXEN-1-YL-PYRIDIN-2-YL-1H-PYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1A1, GUCY1A2, GUCY1B2 | QDPR 446/4885KDM4E 1992/4885ALDH1A1 546/4885 |
| US-20170197950-A1 | THIOPHEN-2-YL-PYRIDIN-2-YL-1H-PYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1B2, GUCY1A2, GUCY1A1 | QDPR 315/4885KDM4E 2888/4885ALDH1A1 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.